VABYSMO®

Looking to VABYSMO® online for your practice? Contact Med Supply Solutions for guidance. VABYSMO® is a prescription injection used for the treatment of neovascular age-related macular degeneration and diabetic macular edema. This treatment operates by inhibiting two critical pathways—angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). These pathways are involved in the formation and leakage of blood vessels in the eye. Unlike some other therapies, clinical studies show that VABYSMO® can maintain its efficacy with up to four-month dosing intervals.

Unlock a World of Possibilities by Signing Up.If our initial offerings haven't caught your eye, there's more we can do. Register for specialized product consultations aimed at exploring the full potential of your clinic's services.

What Is VABYSMO® Used For?

VABYSMO® is primarily prescribed to treat two serious retinal conditions: neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). These conditions can cause serious vision impairment and blindness in adults. The way VABYSMO® injection works is by blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), which are involved in vascular leakage and inflammation. It’s an approach designed to stabilize the blood vessels and slow down the progression of the disease. When considering where to buy Vabysmo® online, medical professionals must use authorized pharmaceutical platforms to ensure they receive genuine products for treatment. This ensures both the safety and the effectiveness of the treatment for patients suffering from these advanced retinal diseases.

VABYSMO® Dosage and Administration Technique

The recommended dosage of VABYSMO® INJECTION 120MG is 6 mg, and it’s administered as an intravitreal injection. In the beginning, patients should receive this dosage every four weeks for the first four injections. Depending on how the patients react, the dosing schedule may then be adjusted so that some patients start receiving the 6 mg dose less frequently—every eight weeks or even every 12 weeks. The patients’ responses are measured with regular monitoring of visual acuity and anatomical changes using optical coherence tomography (OCT). VABYSMO® needs to be administered strictly by a healthcare professional and in a clinical setting to make sure patients are safe. Also, doctors should always order VABYSMO® online from suppliers that guarantee cold-chain integrity and authenticity.

VABYSMO® Side Effects

There are several side effects associated with VABYSMO®, and the most common ones are conjunctival hemorrhage—blood in the white part of the eye—and increased intraocular pressure. They can lead to serious vision-related complications if not properly managed. Other less common but serious side effects include increased intraocular pressure and the potential for infection post-injection, which require immediate medical attention if they occur. To lower any unwanted reactions, doctors should always screen patients for any existing eye infections or inflammation. Additionally, if your patient is pregnant, planning to become pregnant, or breastfeeding, you should discuss the potential risks with them, as VABYSMO® can be harmful in that case. Medical professionals considering whether to buy VABYSMO® wholesale should be aware of these risks and inform their patients before the treatment begins.

VABYSMO® vs. Competition

Eylea is one of the direct competitors of VABYSMO®, which also treats neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). However, unlike VABYSMO®, it only targets VEGF-A, while VABYSMO® has a dual inhibition mechanism, targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Compared to Eylea, VABYSMO® allows for more extended dosing intervals, potentially reducing the frequency of injections. Elyea needs to be administered every one to two months. Meanwhile, VABYSMO® can be used every two, three, or even four months. It all depends on the patient's response and treatment success. Although Eylea is a strong competitor, there are several reasons why doctors buy VABYSMO® :

Dual inhibition (targets angiopoietin-2 (Ang-2) and VEGF-A)
Extended dosing intervals (this depends on the patient’s response)
Treatment flexibility (individual for every patient)

Long-Term Outcomes with VABYSMO®

There have been positive outcomes with VABYSMO® treatments for vision health. Studies show that VABYSMO® improves vision and effectively manages retinal drying over extended periods—up to 72 weeks. This is particularly significant in the treatment of conditions like macular edema following retinal vein occlusion (RVO), as it can improve a patient's quality of life. Patients can have clearer vision and less ocular discomfort over prolonged periods. Apart from experiencing significant gains in vision, patients also have less swelling from fluid retention in the eye. Also, the reduction in swelling is critical, as persistent edema can lead to further complications, including vision loss.

Where Can I Buy VABYSMO®?

Healthcare professionals and clinics who wish to purchase VABYSMO® should always do it through authorized specialty distributors. If you’re not familiar with any authorized distributor who has this treatment, our team will be happy to assist you with that at any time. It is crucial to use only these authorized channels to guarantee product authenticity and patient safety, and to comply with regulatory requirements.

Products

Cart